These authors contributed equally to this paper.
Advances in the treatment of acute graft-versus-host disease
Version of Record online: 26 JUN 2013
© 2013 The Authors. Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Cellular and Molecular Medicine
Volume 17, Issue 8, pages 966–975, August 2013
How to Cite
Qian, L., Wu, Z. and Shen, J. (2013), Advances in the treatment of acute graft-versus-host disease. Journal of Cellular and Molecular Medicine, 17: 966–975. doi: 10.1111/jcmm.12093
- Issue online: 29 AUG 2013
- Version of Record online: 26 JUN 2013
- Manuscript Accepted: 15 MAY 2013
- Manuscript Received: 21 FEB 2013
- National Natural Science Foundation of China. Grant Number: 81072241
- Acute graft-versus-host disease;
- stem cell transplantation;
Allogeneic hematopoietic stem cell transplantation (HSCT) has been widely used for the treatment of hematologic malignant and non-malignant hematologic diseases and other diseases. However, acute graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic transplantation. Acute GVHD may occur in 30% of transplant recipients, which is a syndrome of erythematous skin eruption, cholestatic liver disease and intestinal dysfunction, resulting from the activation of donor T lymphocytes by host antigen-presenting cells, resulting in an immune-mediated inflammatory response. Recent scientific advances in the understanding of the pathogenesis involved in the development of acute GVHD and clinical investigation have provided more effective therapeutic strategies for acute GVHD. This review focuses on major scientific and clinical advances in the treatment of acute GVHD.